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Abstract 
  
Previous studies on the impact of hexavalent chromium [Cr(VI)] on mammalian cell 
energetics revealed alterations suggestive of a shift to a more fermentative metabolism. 
Aiming at a more defined understanding of the metabolic effects of Cr(VI) and of their 
molecular basis, we assessed the impact of a mild Cr(VI) exposure on critical bioenergetic 
parameters (lactate production, oxygen consumption and intracellular ATP levels). Cells 
derived from normal human bronchial epithelium (BEAS-2B cell line), the main in vivo target 
of Cr(VI) carcinogenicity, were subjected for 48 h to 1 μM Cr(VI). We could confirm a shift to a 
more fermentative metabolism, resulting from the simultaneous inhibition of respiration and 
stimulation of glycolysis. This shift was accompanied by a decrease in the protein levels of the 
catalytic subunit (subunit β) of the mitochondrial H+-ATP synthase (β-F1-ATPase) and a 
concomitant marked increase in those of glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH). The corresponding alteration in the β-F1-ATPase/GAPDH protein ratio (viewed as a 
bioenergetic signature) upon Cr(VI) exposure was in agreement with the observed 
attenuation of cellular respiration and enhancement of glycolytic flux. Altogether, these 
results constitute a novel finding in terms of the molecular mechanisms of Cr(VI) effects. 
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1. Introduction 
 
Heavy exposure to Cr(VI) compounds, extensively used in chemical, metallurgical and 
refractory industries, has been firmly associated with an increased risk of lung cancer and of a rare 
cancer of the sinonasal cavity (IARC, 1990; NTP, 2011). The general population may also be at 
risk, as these occupational carcinogens are now widespread in the environment, due to landfill 
disposal of Cr(VI)-containing waste, automobile emissions and fuel combustion, amongst other 
causes (Urbano et al., 2008). Similar to all other cancers, Cr(VI)-induced lung cancer is likely 
associated with dynamic changes in the genome. Accordingly, much research effort has been 
devoted to the study of Cr(VI) genotoxicity. Interestingly, Cr(VI) itself does not react extensively 
with DNA, but its intracellular reduction generates a variety of DNA damaging species. Amongst 
these species are trivalent chromium [Cr(III)], the final product of this reduction (Zhitkovich, 
2005), and strong oxidants such as tetravalent chromium [Cr(IV)], pentavalent chromium [Cr(V)] 
and, possibly, reactive oxygen species (ROS) (Myers, 2012). Altogether, these reactive species 
induce a wide spectrum of potentially mutagenic DNA lesions (adducts, strand breaks, oxidized 
bases, abasic sites and crosslinks) and other genetic defects (Urbano et al., 2012; Urbano et al., 
2008). Significantly, in the TP53 gene, which encodes p53, a critical "guardian of the genome" 
(Lane, 1992), Cr(III) binds preferentially to -NGG- sequences (Arakawa et al., 2006). As these are 
the sequences of three mutational TP53 hotspots in human lung cancer, it is conceivable that 
Cr(III)-DNA adducts might induce mutations in TP53 that, in turn, will facilitate the accumulation, 
along hundreds of generations, of further mutations in this and other genes needed for uncontrolled 
cellular proliferation. 
Notwithstanding the fundamental role that mutations in established cancer genes play in 
carcinogenesis, it is becoming increasingly clear that defects in the mechanisms that govern normal 
cell proliferation, cell death and tissue homeostasis do not lead, per se, to tumor formation. Incipient 
cancer cells must also rewire their metabolism in order to meet the augmented demands for energy, 
reducing power and biosynthetic precursors associated with uncontrolled proliferation (Hanahan 
and Weinberg, 2011). To this day, the best-characterized metabolic phenotype of cancer cells is a 
strong reliance on lactic fermentation for energy generation, despite the presence of an adequate 
oxygen supply (Warburg, 1930). First unveiled by Otto Warburg in the 1920s, this shift to “aerobic 
glycolysis” came to be known as the Warburg effect. 
The exact molecular basis of the Warburg effect remains essentially unknown, but it has 
been reported that, in several common human cancers, it correlates closely with decreased levels of 
the mitochondrial marker β-F1-ATPase, compared to paired normal tissues (Chen et al., 2004; 
Cuezva et al., 2004; Cuezva et al., 2002; He et al., 2004; Isidoro et al., 2004), which suggests a loss 
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of mitochondrial potential for energy generation. On the contrary, the same cancers exhibited 
frequently augmented levels of the glycolytic marker GAPDH (Aldea et al., 2011; Cuezva et al., 
2002; Isidoro et al., 2005; Isidoro et al., 2004; Unwin et al., 2003), pointing to an increased 
glycolytic competence. Altogether, these changes translate into a lower β-F1-ATPase/GAPDH 
protein ratio, which has been defined a bioenergetic signature (Sanchez-Arago et al., 2013). Very 
importantly, it was found that the in vivo tumor glucose uptake of lung carcinomas correlated 
inversely with this ratio (López-Ríos et al., 2007) and it was shown that, for some of these cancers, 
this bioenergetic signature might be used as a marker for cancer progression (Cuezva et al., 2004; 
Cuezva et al., 2002; Isidoro et al., 2005; Lin et al., 2008). It was also suggested that H+-ATP 
synthase downregulation could be used as a predictive marker of tumor response to chemotherapy 
(Shin et al., 2005). 
Impact of Cr(VI) exposure in mammalian cell bioenergetics remains largely unexplored. 
There is already evidence that it inhibits respiration and negatively affects the cellular energy status, 
and there are also some reports of changes in nutrient uptake and in aerobic glycolysis (Abreu et al., 
2014), but the establishment of Cr(VI)-induced metabolic trends and a clear understanding of their 
effective role in Cr(VI)-induced carcinogenesis requires much more additional work. In this study, 
we assessed the impact of a short-term (48 h) exposure to a low Cr(VI) concentration (1 µM) on the 
bioenergetic phenotype of human epithelial bronchial cells. Aiming at an elucidation of the 
underlying mechanisms of the changes that were observed, we also assessed the effects of this 
exposure on the cells' bioenergetic signature, intracellular ATP levels and levels of oxidative stress. 
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2. Materials and methods 
 
2.1. Cell culture 
 
BEAS-2B cells, obtained from the European Collection of Animal Cell Cultures (Salisbury, 
UK; ECCAC no. 95102433) were used throughout this study. These cells were grown in a serum-
free medium (Gibco® LHC-9 medium, from Invitrogen). Cultures were established in tissue culture-
grade flasks or multiwell plates pre-coated with gelatine (from bovine skin, type B, Sigma-Aldrich) 
and maintained at 37 °C in a humidified atmosphere of 95% air/5% CO2. Cells were seeded at 4000 
cells/cm2 and subcultured at 70%–80% confluence (typically, 3–4 days after seeding). Under these 
culture conditions, the stationary phase of growth was never reached. Cultures used in the different 
experiments were in passages 11 to 19. 
 
2.2. Cr(VI) exposures 
 
In all experiments, cells were allowed to attach to the substrate for 24 h prior to the addition 
of Cr(VI). Final concentrations of Cr(VI), ranging between 0.1 and 2.0 µM, were achieved through 
addition to the growth medium of adequate volumes of filter-sterilized 5 or 50 µM K2Cr2O7 
(Sigma-Aldrich) aqueous solutions. Control cultures, established and processed in parallel, received 
an equivalent amount of the vehicle (water). 
 
2.3. Colony formation assay 
 
Clonogenic potentials were determined using the colony formation assay, as described by 
Franken and collaborators (Franken et al., 2006). Briefly, cells were seeded into 6-well plates (300 
cells/well) and subjected to different Cr(VI) exposures. At least two cultures were prepared for each 
condition. Nine or ten days after seeding, colonies were fixed and stained with a solution containing 
6.0% (v/v) glutaraldehyde (Sigma-Aldrich) and 0.5% (w/v) crystal violet (Sigma-Aldrich). Colonies 
were counted by direct observation, scoring all colonies that stained purple. For the calculation of 
plating efficiencies, defined as the ratio, in percentage, of number of colonies formed to number of 
cells seeded, the number of colonies in the replicate cultures was averaged. 
 
2.4. Determination of protein contents 
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In those experiments where results were standardized to protein content, trypsinized cultures 
were washed with phosphate-buffered saline (PBS), resuspended in an adequate volume of lysis 
buffer [10 mM tris base (Sigma-Aldrich), pH 7.5; 130 mM NaCl; 1% (v/v) Triton X-100 (Merck); 
ethylenediaminetetracetic acid (EDTA)-free protease inhibitor cocktail (1 tablet per 0,95 mL buffer; 
Roche, Cat. No. 11 836 170 001)] and centrifuged at 11,000 g and 4 °C for 15 min. Supernatants 
were transferred to new centrifuge tubes and their protein contents were determined by the Bradford 
method (Bradford, 1976), using the Bio-Rad protein assay dye reagent concentrate (Bio-Rad) and 
bovine serum albumin as a standard. 
 
2.5. Determination of oxygen consumption rates 
 
Oxygen consumption rates (OCRs) were measured using the Seahorse XF24 Extracellular 
Flux Analyzer (Seahorse Bioscience). For these determinations, cells were seeded into the wells of 
a XF 24-well cell culture microplate (20,000 cells/well in 250 µL of medium). Eight replicate 
cultures were used for each condition. At the end of the Cr(VI) exposure, spent medium was 
replaced with 700 µL of fresh, Cr(VI)-free medium and cells were incubated at 37 °C for 60 min to 
allow for media temperature and pH to reach equilibrium. After obtaining the basal OCR, 
oligomycin (Sigma-Aldrich), 2,4-dinitrophenol (2,4-DNP, Sigma-Aldrich), rotenone (Sigma-
Aldrich) and antimycin (Sigma-Aldrich) were sequentially added to each well (in 50 µL of LHC-9 
medium) to final concentrations of 6 µM, 750 µM, 1 µM and 1 µM, respectively. OCRs under these 
different conditions were measured between additions. OCRs were expressed in pmol O2/min/µg 
protein. 
 
2.6. Determination of lactate production 
 
For these determinations, cells were seeded into 6-well plates (100,000 cells/well). 
Tetraplicate cultures were used for each condition. At the end of the Cr(VI) exposure, spent 
medium was replaced with fresh, Cr(VI)-free medium, with or without 6 µM oligomycin or 750 µM 
2,4-DNP. Incubations with oligomycin lasted 4 h and those with 2,4-DNP 1 h. After the 
incubations, the decrease in lactate levels in the growth medium over a 4 h period was determined. 
To this end, 200 µL aliquots of growth medium were collected at times 0 and 4 h and treated with 
6% (v/v) perchloric acid (Merck) to stop lactate dehydrogenase enzymatic activity. After 30 min on 
ice, the samples were centrifuged, for 5 min, at 11,000 g and 4 °C. Supernatants, kept on ice, were 
neutralized with 20% (w/v) KOH (Merck) and centrifuged at 11,000 g and 4 °C for 5 min to 
sediment the KClO4 salt. Lactate levels in the clear supernatants were determined using a lactate 
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dehydrogenase (LDH)-based enzymatic assay. For standardization purposes, protein contents were 
determined as described in section 2.4. The rate of lactate production was expressed in nmol 
lactate/h/µg protein. 
 
2.7. Determination of intracellular ATP levels 
 
Intracellular levels of ATP were determined enzymatically using the ATP Bioluminescence 
Assay Kit HS II (Roche), which is based on the ATP dependency of the light emitting oxidation of 
luciferin, catalyzed by luciferase (Deluca et al., 1978). Cultures were prepared in 6-well plates 
(seeding density of either 100,000 or 150,000 cells/well), using triplicate cultures for each 
condition. At the end of the Cr(VI) exposure, spent medium was replaced with fresh, Cr(VI)-free 
medium with or without 6 µM oligomycin, 750 µM 2,4-DNP or 100 µM 2-deoxyglucose (2-DG, 
Sigma-Aldrich). After a one-hour incubation, cells were collected by trypsinization and disrupted 
by addition of 400 µL of boiling ATP lysis buffer [100 mM tris base, pH 7.75; 4 mM EDTA]. After 
2 min at 95 °C, extracts were centrifuged at 11,000 g for 15 min. ATP solutions with concentrations 
ranging from 1.6 × 10–9 to 1.6 × 10–6 M were used as standards. Luminescence was measured using 
a FLUOstar OPTIMA plate luminometer (BMG Labtech). Intracellular ATP levels were expressed 
in nmol ATP/106 cells.  
 
2.8. Western blot analysis 
 
Proteins from cellular extracts were fractionated by SDS-PAGE. The fractionated proteins 
were transferred to a polyvinylidene fluoride (PVDF) membrane for immunoblot analysis. Mouse 
primary monoclonal antibodies were used for Hsp60 and GAPDH detection (Enzo Life Sciences 
and Abcam, respectively), whereas a polyclonal rabbit antibody was used for β-F1-ATPase 
detection (Cuezva et al., 2002). Peroxidase-conjugated anti-mouse or anti-rabbit IgGs (Nordic 
Immunology) were used as secondary antibodies. The dilutions used were 1:20,000 for the primary 
antibodies and 1:5000 for the secondary antibodies. The blots were developed using the Novex® 
ECL chemiluminescent reagent kit (Invitrogen). Expression levels in control and Cr(VI)-exposed 
samples were normalized relative to those of the same proteins found in HCT116 cells extracted in 
parallel and assayed in the same gels and expressed relative to the mean value of unexposed cells. 
 
2.9. Assessment of oxidative stress 
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Oxidative stress was assessed in cultures established in 6-well plates (100,000 cells/well). 
Tetraplicate cultures were used for each condition. After Cr(VI) exposure, control and Cr(VI)-
exposed cultures were incubated for 1 h in fresh, Cr(VI)-free medium with or without 6 µM 
oligomycin. Cell pellets, obtained by trypsinization, were resuspended in 300 µL of a 5 µM 2’,7’-
dichlorodihydrofluorescein diacetate (DCFH-DA) solution (Invitrogen) and placed at 37 °C for 30 
min (protected from light). The cellular suspensions were then centrifuged at 1500 rpm for 5 min 
and the resulting pellets were dispersed into 200 µL of a buffer containing 1.0% (v/v) fetal bovine 
serum (Gibco) and 0.1% (w/v) sodium azide in PBS. Propidium iodide (PI; 1 µL; Sigma-Aldrich) 
was added to each sample to detect dead cells. The fluorescence emitted by 2’,7’-
dichlorofluorescein (DCF) and PI was detected by flow cytometry using a FACSCalibur System 
(BD Biosciences). The flow cytometer was equipped with two lasers, 488 nm (Blue) and 663 nm 
(Red), and four fluorescence detectors, FL1 (Blue, 530/30 nm), FL2 (Blue, 585/42 nm), FL3 (Blue, 
670 nm LP) and FL4 (Red, 660/14 nm). DCF and PI emissions were collected through the FL1 and 
FL3 channels, respectively. Acquisition and analysis of gates were set using BD CellQuest Pro 
software. Briefly, live cells were identified based on PI dye exclusion and intact cells based on the 
FSC-H and SSC-H parameters. Then, DCF-positive cells were identified. At least 10,000 events 
were recorded in each determination. 
 
2.10. Statistical analysis 
 
Multiple variances (time and concentration) present in the clonogenic assays were statistically 
analysed with the two-way ANOVA model and the Bonferroni’s post hoc test. The results are 
represented as the mean ± standard error of the mean (SEM). Differences with p < 0.05 were 
considered statistically significant. The analysis was performed with the Graphpad Prism Software. 
All other results were statistically analysed with the unpaired Student’s t test, using the Excel 
software. The results are represented as the mean ± SEM. Differences with p < 0.05 were 
considered statistically significant. 
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3. Results 
 
3.1. Short-term exposure to Cr(VI) in the low micromolar range had little impact on the 
clonogenic potential of BEAS-2B cells 
 
Overtly cytotoxic exposure regimens are of questionable relevance in the context of 
carcinogenesis. To select an appropriate regimen for our evaluation of the impact of Cr(VI) on 
bioenergetics, we first assessed the cytotoxicity of various exposure regimens. The colony-forming 
assay was used to this end. As can be seen (Figure 1), with the exception of the decreases in 
clonogenic potential produced by the highest Cr(VI) concentration tested (2 µM), all other 
decreases were rather small and devoid of statistical significance. Interestingly, after an initial 
decrease, the clonogenic potential of cells exposed to 0.5 µM Cr(VI) increased over time of 
exposure. Despite the absence of statistical significance, this increase in clonogenic potential over 
time for Cr(VI)-exposed cells is in line with a stimulation of proliferation suggested in two previous 
studies by our group with the same cell line and exposure regimen, but using different endpoints of 
toxicity (dehydrogenase activity (Costa et al., 2010) and trypan blue dye exclusion (Ferreira et al., 
2011). Cytotoxicity data reported by Caglieri and co-workers also suggested a stimulation of 
proliferation upon exposure to Cr(VI) in the low micromolar range (Caglieri et al., 2008). Based on 
these results, an exposure regimen consisting of a 48 h exposure to 1 µM Cr(VI) was adopted. 
 
< Figure 1 > 
 
3.2. Cr(VI) compromised the respiratory capacity of BEAS-2B cells 
 
To characterize the impact of the adopted Cr(VI) exposure regimen on cellular respiration, 
OCRs were determined for control and Cr(VI)-exposed cells. These determinations were carried out 
both under basal conditions and after sequentially exposing cells to four well-defined modulators of 
oxidative phosphorylation (OXPHOS): oligomycin (an inhibitor of the mitochondrial H+-ATP 
synthase), 2,4-DNP (which uncouples electron transport from ATP synthesis), rotenone (an 
inhibitor of complex I of the mitochondrial electron transport chain (ETC)) and antimycin (an 
inhibitor of complex III of the ETC). The real-time profiles obtained using the Seahorse XF24 
Extracellular Flux Analyzer can be seen in Figure 2a. Control and Cr(VI)-exposed cells responded 
identically to the three inhibitors tested, but OCRs were always slightly attenuated in Cr(VI)-
exposed cells, as compared to the corresponding controls, an effect also observed under basal 
conditions. Differences in OCRs between control and Cr(VI)-exposed cells were much more 
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pronounced under uncoupling conditions, i.e., when dissipation of the mitochondrial proton 
gradient maximized mitochondrial respiration. As can be appreciated in Figure 2, while control 
cells responded to 2,4-DNP addition by a significant upregulation of mitochondrial respiration (by 
ca. 40%, compared to basal values), Cr(VI)-exposed cells exhibited a modest upregulation. 
Altogether, the results suggest that Cr(VI) compromised the respiratory capacity of BEAS-2B cells 
and that respiration of Cr(VI)-exposed cells under basal conditions was already close to its 
maximum. 
 
< Figure 2 > 
 
3.3. Cr(VI) augmented the glycolytic capacity of BEAS-2B cells  
 
Next, we assessed the impact of the same Cr(VI) exposure on aerobic glycolysis, by 
comparing the rates of lactate production by Cr(VI)-exposed cells with those of control cells. 
Determinations were conducted both under basal conditions and under conditions that impaired 
OXPHOS-mediated ATP synthesis (Figure 3). Basal lactate production rates were slightly higher in 
Cr(VI)-exposed cells than in control cells. Oligomycin elicited a small stimulation of lactate 
production, which was essentially identical in both control and Cr(VI)-exposed cells. Once again, 
differences between control and Cr(VI)-exposed cells became more evident in the presence of 2,4-
DNP. In fact, the upregulation of lactate production induced by this uncoupler in Cr(VI)-exposed 
cells was much stronger than that induced in control cells, which suggests an increased glycolytic 
capacity for Cr(VI)-exposed cells. 
 
< Figure 3 > 
 
3.4. Intracellular ATP levels of BEAS-2B cells remained essentially unaltered upon Cr(VI) 
exposure 
 
Intracellular ATP levels in control and Cr(VI)-exposed cells were determined under basal 
conditions and under conditions that impaired glycolytic or OXPHOS-mediated ATP synthesis 
(Figure 4). Despite their attenuated OCRs, Cr(VI)-exposed cells exhibited ATP levels comparable 
to those of the corresponding controls under all four experimental conditions tested. The 
accompanying rise in aerobic glycolysis described in the previous section might have contributed to 
this compensatory mechanism. Inhibition of OXPHOS by oligomycin provoked a dramatic drop in 
ATP levels in both control and Cr(VI)-exposed cells, revealing that fermentation alone was unable 
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to maintain basal ATP levels. This result indicates that BEAS-2B cells normally regenerate ATP 
mostly by electron transfer phosphorylation. An identically dramatic drop in intracellular ATP 
levels was observed upon incubation with 2-DG, a competitive inhibitor of hexokinase, the first 
enzyme of glycolysis. This observation shows that these cells were deriving most of their energy 
from the oxidation of glucose, and not from the oxidation of glutamine, a fuel molecule also present 
in the growth medium used. Although substantial, the decrease in intracellular ATP levels observed 
under uncoupling conditions was much less pronounced than those observed in the presence of 
oligomycin or 2-DG. The ability of 2,4-DNP to strongly upregulate glycolysis might have 
contributed to this result. 
 
< Figure 4 > 
 
3.5. Changes in the expression of GAPDH and β-F1-ATPase induced by Cr(VI) exposure 
translated into an altered bioenergetic signature  
 
Our investigation into the mechanisms by which Cr(VI) altered the bioenergetic phenotype 
of BEAS-2B cells included the evaluation of the effects of this carcinogen on the protein levels of 
GAPDH and β-F1ATPase, which can be used as markers of glycolytic and OXPHOS activity, 
respectively. These determinations, which were carried out by Western blot analysis, showed that 
the levels of these two proteins were differentially affected by Cr(VI): whereas GAPDH levels were 
increased by nearly 50%, levels of β-F1ATPase were slightly decreased (Figure 5). As a 
consequence, the β-F1-ATPase/GAPDH protein ratio, viewed as a cellular bioenergetic signature 
(Sanchez-Arago et al., 2013), was significantly diminished in Cr(VI)-exposed cells. 
 
< Figure 5 > 
 
3.6. Oligomycin treatment significantly increased levels of oxidative stress in Cr(VI)-exposed 
cells  
 
In order to further investigate the mechanisms of Cr(VI)-induced changes in the 
bioenergetic phenotype of BEAS-2B cells, levels of oxidative stress were assessed, by flow 
cytometry and using the redox probe DCFH-DA, in control and Cr(VI)-exposed cells. These 
determinations were carried out both under basal conditions and in the presence of oligomycin 
(Figure 6). Basal levels of oxidative stress were identical in control and Cr(VI)-exposed cells (the 
small increase observed upon Cr(VI) exposure was not statistically significant). However, whereas 
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control cells were able to prevent an increase in oxidative stress when challenged by oligomycin 
treatment, Cr(VI)-exposed cells were not (Figure 6b). This result might indicate a negative impact 
of Cr(VI) on the cellular antioxidant defenses. 
 
< Figure 6 > 
 
4. Discussion 
 
In 1990, based on extensive epidemiological, animal and other relevant studies, the 
International Agency for Research on Cancer (IARC) classified Cr(VI) compounds as encountered 
in the chromate production, chromate pigment production and chromium plating industries as 
carcinogenic to humans (IARC, 1990). The observations made by our group upon exposure of 
human bronchial epithelial cells, the main targets of Cr(VI) toxicity, to low Cr(VI) concentrations 
are in line with this classification. These observations included changes in morphology and pattern 
of growth characteristic of an early phase of pre-malignant progression (Costa et al., 2010) and 
overexpression of genes commonly involved in malignant transformation (e.g., MYC) (Rodrigues et 
al., 2009). Yet, despite the combined efforts of many research groups, the molecular basis of Cr(VI) 
carcinogenicity remains elusive (Urbano et al., 2012). Namely, clarification is needed on the impact 
of Cr(VI) compounds on mammalian cell bioenergetics. In spite of various reports on changes in 
critical bioenergetic parameters induced by Cr(VI) exposure (Abreu et al., 2014; Urbano et al., 
2012), specific Cr(VI)-induced bioenergetic phenotypes have not yet been firmly established. The 
main aim of the present study was to produce additional, biologically relevant data regarding this 
aspect. 
The increased risk of chromate lung cancer is associated with the inhalation of Cr(VI) 
particles (Barceloux, 1999). These particles adhere to the surface of bronchial epithelial cells and 
slowly release, in their close vicinity, soluble Cr(VI) oxyanions. Some of these ions, present 
essentially in the form of chromate, escape extracellular reduction and readily cross cell membranes 
(Alexander and Aaseth, 1995; Sehlmeyer et al., 1990). Once in the intracellular milieu, they 
undergo reduction and various reactive species are formed that cause cellular damage (Myers, 2012; 
Zhitkovich, 2005). 
To address the issue of biological relevance, we employed a cell line (BEAS-2B) that was 
derived from normal human bronchial epithelium. Although immortalized through viral infection, 
BEAS-2B cells retain features of human bronchial epithelial cells and only became tumorigenic 
(very weakly) at passages much higher than those used in this study (Reddel et al., 1988; Reddel et 
al., 1993). In the present study, BEAS-2B cells were submitted to 1 µM Cr(VI) for 48 h, an 
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exposure regimen that was not overtly cytotoxic to them, as demonstrated by us in this and previous 
studies (Costa et al., 2010; Ferreira et al., 2011), using three different endpoints of toxicity. Also, 
according to a study by Caglieri and collaborators, BEAS-2B cells exposed to this Cr(VI) 
concentration for both 8 and 24 h results exhibited an intracellular Cr content (ca. 50 µg/g of cells) 
(Caglieri et al., 2008) that compares well with the mean Cr content found by Tsunetta and co-
workers in the peripheral lung tissue of chromate workers with lung cancer (36.7 µg/g wet weight) 
(Tsuneta et al., 1980). The impact of the chosen Cr(VI) exposure regimen on the bioenergetic 
phenotype of BEAS-2B cells was assessed in terms of cellular respiration, aerobic glycolysis and 
intracellular ATP levels. Determinations were carried out both under basal conditions and in the 
presence of well-defined bioenergetic effectors. 
Bioenergetic analysis with the XF24 Extracellular Flux Analyzer demonstrated that a single 
insult with 1 µM Cr(VI) compromised the respiratory capacity of BEAS-2B cells. This effect was 
best appreciated under uncoupling conditions, which forced the ETC to operate at its maximal 
capacity. Inhibition of respiration occurred concurrently with a stimulation of aerobic glycolysis. 
Similar to its effect on respiration, the effect of Cr(VI) on aerobic glycolysis was rather modest 
under basal conditions or in the presence of oligomycin, but became more pronounced under 
uncoupling conditions, which collapsed the mitochondrial membrane potential (∆ψm). It is of note 
that the stimulation of aerobic glycolysis produced by the uncoupler was significantly higher in 
Cr(VI)-exposed cells than in control cells. This observation suggests that Cr(VI) increased the 
maximal glycolytic capacity of BEAS-2B cells. Upregulation of aerobic glycolysis in response to 
Cr(VI) had been observed previously by our group in PC-12 cells (a cancer cell line) exposed for 6 
h to 1–5 µM Cr(VI) (Gonçalves et al., 2011) and in BEAS-2B cells over a 6-week exposure to 0.1 
and 1.0 µM Cr(VI) (Ferreira et al., 2011). In both cases, upregulation of aerobic glycolysis was 
accompanied by increases in glucose uptake rates. 
The stronger reliance of cancer cells on a less efficient process of energy production is 
seemingly paradoxical, as these rapidly proliferating cells likely require more energy than their 
normal counterparts. Thus, the consistency of this bioenergetic phenotype among cancer cells 
strongly points to an impaired respiration, as proposed by Warburg, and/or to the acquisition of 
selective growth advantages not directly related to energy production. In spite of much speculation, 
these advantages remain essentially undefined. They might be related, for instance, to the 
generation of intermediates and reducing power for biosynthesis and/or to the acidification of the 
extracellular milieu (Cardone et al., 2005; Sanchez-Arago et al., 2013). Active biosynthesis is 
required to sustain proliferation and the acidification of the extracellular milieu, which accompanies 
lactate upregulation, has been shown to promote, in several model systems, neoangiogenesis, 
anchorage-independent growth, genetic instability, facilitating invasion. Interestingly, in these 
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model systems, acidification occurred early in transformation (Cardone et al., 2005). Therefore, it is 
possible that the shift to a more fermentative metabolism observed in our study upon short-term 
incubation (48 h) of BEAS-2B cells to Cr(VI) constitutes an early step in Cr(VI)-induced lung 
cancer. 
The ability of both control and Cr(VI)-exposed BEAS-2B cells to upregulate aerobic 
glycolysis in response to oligomycin-induced OXPHOS inhibition was very limited. As a 
consequence, their intracellular ATP levels decreased dramatically. On the contrary, these cells 
were able to more than double their rates of aerobic glycolysis when stressed with 2,4-DNP. 
Nonetheless, the upregulation of aerobic glycolysis was still insufficient to ensure basal ATP levels. 
Very pronounced decreases in ATP levels were also observed in the presence of 2-DG, which 
suggests that BEAS-2B cells are not able to use glutamine, present in the growth medium in levels 
analogous to those of glucose, as a major energy source. Lastly, differences in ATP levels between 
control and Cr(VI)-exposed cells were very modest under all four experimental conditions tested 
(the differences were never statistically significant). 
Attenuation of respiration by Cr(VI) has been consistently reported in the literature, both in 
cultured cells and in isolated mitochondria (Abreu et al., 2014). However, the underlying 
mechanisms of this attenuation are poorly understood. It has been speculated that oxidation of 
NADH and NAD-linked substrates (e.g., glutamate and citrate) by Cr species might compromise 
substrate availability to the ETC (Ryberg and Alexander, 1984, 1990). It is also possible that 
processes of ATP generation are compromised due to the formation of stable coordination 
complexes between Cr(III) and ATP precursors and/or proteins involved in these processes (Abreu 
et al., 2014). There are, in fact, reports of changes in the activities of these enzymes upon Cr(VI) 
exposure, as well as changes in their intracellular levels and in the expression of the corresponding 
genes (Abreu et al., 2014). However, these changes were heavily dependent on the model systems 
employed, preventing the establishment of reliable trends. It is, nonetheless, worth mentioning that 
complex I of the ETC was found inhibited in six out of seven reported studies, and complex III was 
found inhibited in five out of six (Fernandes et al., 2002; Garcia-Nino et al., 2013; Messer et al., 
2000; Molina-Jijon et al., 2011; Myers et al., 2010; Xiao et al., 2012a; Xiao et al., 2012b). One of 
these studies assessed also the effects on aconitase, reporting the inhibition of this tricarboxylic acid 
(TCA) cycle enzyme (Myers et al., 2010). By attenuating the TCA cycle, aconitase inhibition might 
slow down the production of NADH, the source of electrons to complex I, ultimately attenuating 
respiration. In fact, fluorocitrate, a specific inhibitor of aconitase, inhibited respiration (Gardner et 
al., 1994). 
The immunologic analysis carried out in the present study provided additional insight into 
the molecular basis of the observed Cr(VI)-induced bioenergetic effects. In this analysis, GAPDH 
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and β-F1-ATPase were used as markers of glycolytic and OXPHOS activities, respectively. It is of 
note that β-F1-ATPase, which is the catalytic subunit of the H+-ATP synthase complex, is a rate-
limiting component of OXPHOS. The results obtained are in line with the impaired respiration and 
augmented glycolytic potential just discussed: β-F1-ATPase proteins levels were decreased, 
whereas those of GAPDH were increased. Altogether, this dual effect resulted into a lower β-F1-
ATPase/GAPDH protein ratio, similar to what has been described in common human cancers 
(Aldea et al., 2011; Cuezva et al., 2002; Isidoro et al., 2004).  
We next investigated the possible involvement of oxidative stress in the bioenergetic 
changes induced by Cr(VI) exposure, as the intracellular reduction of Cr(VI) is accompanied by the 
generation of strong oxidants, such as Cr(IV), Cr(V) and ROS (Myers, 2012). We observed that the 
impact of Cr(VI) exposure on oxidative stress levels depended on the experimental conditions. 
Under basal conditions, these levels remained basically unaltered, indicating that the antioxidant 
defense system of BEAS-2B cells was able to cope with any upregulation of Cr(IV), Cr(V) and/or 
ROS (the probe used is not able to discriminate between these species (Kalyanaraman et al., 2012)) 
that the Cr(VI) exposure regimen adopted might have produced. On the contrary, levels of oxidative 
stress were much increased when cells were also treated with oligomycin. In the presence of this 
specific inhibitor of the ATP synthase, which blocks its proton channel, protons tend to accumulate 
in the mitochondrial inter-membrane space, triggering an increase of ∆ψm (Sánchez-Cenizo et al., 
2010). In turn, increases in ∆ψm are associated with ROS formation (Hüttemann et al., 2008). 
Whereas control cells were able to maintain their levels of oxidative stress when treated with 
oligomycin, Cr(VI)-exposed cells did not, exhibiting much increased levels of oxidative stress in 
the presence of this inhibitor. This inability of Cr(VI)-exposed cells to counterbalance the increased 
production of ROS likely induced by oligomycin suggests that Cr(VI) compromises the antioxidant 
defenses of BEAS-2B cells. This is in line with previous reports of Cr(VI) interference with some 
components of the antioxidant defense system of mammalian cells (Abreu et al., 2014), namely 
with the thioredoxin system (Myers et al., 2008; Myers and Myers, 2009), which plays a major role 
in the maintenance of the intracellular thiol-disulfide redox balance (Lu and Holmgren, 2014). 
 
5. Conclusions 
 
The results obtained in this study provided mechanistic insights into the metabolic 
reprogramming of lung cancer cells to an enhanced aerobic glycolysis. Specifically, our study 
revealed proteomic changes in Cr(VI)-exposed cells (decreased β-F1-ATPase levels and augmented 
GAPDH levels) that might have translated into a lower mitochondrial potential for energy 
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generation and an increased glycolytic competence. Our results also suggest that Cr(VI) interferes 
with the cellular antioxidant system.  
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 Figure 1 – Short-term exposure (24-72 h) to Cr(VI) in the low micromolar range had 
little or no effect in the colony forming potential of BEAS-2B cells. Values represent the 
mean ± SEM of 3 independent experiments. In each experiment, at least duplicate 
cultures were prepared for each condition. Multiple comparisons by analysis of 
variance were done with two-way ANOVA model and the post hoc Bonferroni’s test 
confirmed that there were no significant differences (p > 0.05).  
 
Figure 2 – Short-term exposure (48 h) to 1 μM Cr(VI) compromised the respiratory 
capacity of  BEAS-2B cells. (A) Bioenergetic profiles obtained using the XF24 
Extracellular Flux Analyzer. The arrows represent the sequential addition of 6 μM 
oligomycin (OL), 750 μM 2,4-dinitrophenol (DNP), 1 μM rotenone (ROT) and 1 μM 
antimycin (ANT). (B) Oxygen consumption rates under basal and uncoupling 
conditions (i.e., after DNP addition) for control and Cr(VI)-exposed cells. Data 
represent the mean ± SEM for 8 determinations. Asterisks indicate p < 0.05 (*) or p < 
0.01 (**), when compared with control values by Student’s t test; Cardinals indicate p < 
0.05 (#) when compared with the respective basal value by Student’s t test. 
 
Figure 3 – Short-term exposure (48 h) to 1 μM Cr(VI) augmented the glycolytic capacity 
of BEAS-2B cells under basal and uncoupling conditions. The results shown are the 
mean ± SEM of the 4 determinations. Asterisks indicate p < 0.05 (*) or p < 0.01 (**), 
when compared with control values by Student’s t test; Cardinals indicate p < 0.01 
(##) or p < 0.001 (###), when compared with the respective basal value by Student’s t 
test. OL, oligomycin; DNP, 2,4-dinitrophenol. 
 
Figure 4 – Intracellular ATP levels of BEAS-2B cells remained unaltered upon short-term 
exposure (48 h) to 1 μM Cr(VI), under all 4 experimental conditions tested. Values 
represent the means ± SEM of 3 independent experiments. Cardinals indicate p < 0.05 
(#), p < 0.01 (##) or p < 0.001 (###), when compared with the respective basal value 
by Student’s t test. 2-DG, 2-deoxyglucose; OL, oligomycin; DNP, 2,4-dinitrophenol. 
 
Figure 5 – Short-term (48 h) exposure to 1 μM Cr(VI) altered the protein levels of 
glycolytic (GAPDH) and mitochondrial (β-F1-ATPase ) markers. (A) Representative 
western blot of the expression of β-F1-ATPase and GAPDH in two different 
preparations of control and exposed cells. (B) Values represent the relative expression 
(i.e., compared to control cultures; mean ± SEM) of β-F1-ATPase (n=14), GAPDH (n=13) 
and β-F1-ATPase:GAPDH ratio. Asterisks indicate p < 0.05 (*) or p < 0.001 (***), when 
compared with control values by Student’s t test. β-F1-ATPase, catalytic subunit 
(subunit β) of the mitochondrial H+-ATP synthase; GAPDH, glyceraldehyde-3-
phosphate dehydrogenase. 
 
Figure 6 – Short-term (48 h) exposure to Cr(VI) augmented oxidative stress levels in 
oligomycin (OL)-treated BEAS-2B cells. Values represent the mean ± SEM of four 
determinations. Asterisks indicate p < 0.001 (***), when compared with control values 
by Student’s t test; Cardinals indicate p < 0.001 (###) when compared with the 
respective basal value by Student’s t test. 
  
Figure 1
  
Figure 2
  
Figure 3
  
Figure 4
  
Figure 5
  
Figure 6
  
 23
Highlights 
 
• Chromium(VI) impaired respiration and increased glycolytic flux in BEAS-2B cells. 
• Cr(VI)-exposed cells shifted to a more fermentative metabolism. 
• This metabolic shift was in line with a decreased β-F1-ATPase/GAPDH protein ratio. 
• Increased oxidative stress levels suggest impairment of antioxidant defenses. 
 
 
